385 related articles for article (PubMed ID: 33283987)
1. Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer.
Lu W; Yu W; He J; Liu W; Yang J; Lin X; Zhang Y; Wang X; Jiang W; Luo J; Zhang Q; Yang H; Peng S; Yi Z; Ren S; Chen J; Siwko S; Nussinov R; Cheng F; Zhang H; Liu M
EMBO Mol Med; 2021 Jan; 13(1):e12798. PubMed ID: 33283987
[TBL] [Abstract][Full Text] [Related]
2. Combination of EP
Wang Y; Cui L; Georgiev P; Singh L; Zheng Y; Yu Y; Grein J; Zhang C; Muise ES; Sloman DL; Ferguson H; Yu H; Pierre CS; Dakle PJ; Pucci V; Baker J; Loboda A; Linn D; Brynczka C; Wilson D; Haines BB; Long B; Wnek R; Sadekova S; Rosenzweig M; Haidle A; Han Y; Ranganath SH
Oncoimmunology; 2021 Mar; 10(1):1896643. PubMed ID: 33796403
[TBL] [Abstract][Full Text] [Related]
3. A RIPK3-PGE
Yan G; Zhao H; Zhang Q; Zhou Y; Wu L; Lei J; Wang X; Zhang J; Zhang X; Zheng L; Du G; Xiao W; Tang B; Miao H; Li Y
Cancer Res; 2018 Oct; 78(19):5586-5599. PubMed ID: 30012671
[TBL] [Abstract][Full Text] [Related]
4. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E receptor 4 (EP4) promotes colonic tumorigenesis.
Chang J; Vacher J; Yao B; Fan X; Zhang B; Harris RC; Zhang MZ
Oncotarget; 2015 Oct; 6(32):33500-11. PubMed ID: 26378024
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice.
Shi M; Shi G; Tang J; Kong D; Bao Y; Xiao B; Zuo C; Wang T; Wang Q; Shen Y; Wang H; Funk CD; Zhou J; Yu Y
J Allergy Clin Immunol; 2014 Nov; 134(5):1163-74.e16. PubMed ID: 24948368
[TBL] [Abstract][Full Text] [Related]
7. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Immunotherapeutic Efficacy of Anti-PD-L1 Antibody in Combination with an EP4 Antagonist.
Sajiki Y; Konnai S; Cai Z; Takada K; Okagawa T; Maekawa N; Fujisawa S; Kato Y; Suzuki Y; Murata S; Ohashi K
Immunohorizons; 2020 Dec; 4(12):837-850. PubMed ID: 33443026
[TBL] [Abstract][Full Text] [Related]
9. Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors.
Francica BJ; Holtz A; Lopez J; Freund D; Chen A; Wang D; Powell D; Kipper F; Panigrahy D; Dubois RN; Whiting CC; Prasit P; Dubensky TW
Cancer Res Commun; 2023 Aug; 3(8):1486-1500. PubMed ID: 37559947
[TBL] [Abstract][Full Text] [Related]
10. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity.
Albu DI; Wang Z; Huang KC; Wu J; Twine N; Leacu S; Ingersoll C; Parent L; Lee W; Liu D; Wright-Michaud R; Kumar N; Kuznetsov G; Chen Q; Zheng W; Nomoto K; Woodall-Jappe M; Bao X
Oncoimmunology; 2017; 6(8):e1338239. PubMed ID: 28920002
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D; Fu L; Sun H; Guo L; DuBois RN
Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
[TBL] [Abstract][Full Text] [Related]
12. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
13. Scaffold Hopping Strategy to Identify Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy.
Wang W; He J; Yang J; Zhang C; Cheng Z; Zhang Y; Zhang Q; Wang P; Tang S; Wang X; Liu M; Lu W; Zhang HK
J Med Chem; 2022 Jun; 65(11):7896-7917. PubMed ID: 35640059
[TBL] [Abstract][Full Text] [Related]
14. The COX-2-PGE2 Pathway Promotes Tumor Evasion in Colorectal Adenomas.
Wei J; Zhang J; Wang D; Cen B; Lang JD; DuBois RN
Cancer Prev Res (Phila); 2022 May; 15(5):285-296. PubMed ID: 35121582
[TBL] [Abstract][Full Text] [Related]
15. PGE2-EP2/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer.
Akbari B; Soltantoyeh T; Shahosseini Z; Jadidi-Niaragh F; Hadjati J; Brown CE; Mirzaei HR
Front Immunol; 2023; 14():1209572. PubMed ID: 37457723
[TBL] [Abstract][Full Text] [Related]
16. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.
Sumida K; Wakita D; Narita Y; Masuko K; Terada S; Watanabe K; Satoh T; Kitamura H; Nishimura T
Eur J Immunol; 2012 Aug; 42(8):2060-72. PubMed ID: 22653638
[TBL] [Abstract][Full Text] [Related]
17. Myeloid Cell Prostaglandin E2 Receptor EP4 Modulates Cytokine Production but Not Atherogenesis in a Mouse Model of Type 1 Diabetes.
Vallerie SN; Kramer F; Barnhart S; Kanter JE; Breyer RM; Andreasson KI; Bornfeldt KE
PLoS One; 2016; 11(6):e0158316. PubMed ID: 27351842
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.
Take Y; Koizumi S; Nagahisa A
Front Immunol; 2020; 11():324. PubMed ID: 32210957
[TBL] [Abstract][Full Text] [Related]
19. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer.
Chen J; Sun HW; Yang YY; Chen HT; Yu XJ; Wu WC; Xu YT; Jin LL; Wu XJ; Xu J; Zheng L
Signal Transduct Target Ther; 2021 Jan; 6(1):4. PubMed ID: 33414378
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the Signaling Modalities of Prostaglandin E2 Receptors EP2 and EP4 Reveals Crosstalk and a Role for Microtubules.
Vleeshouwers W; van den Dries K; de Keijzer S; Joosten B; Lidke DS; Cambi A
Front Immunol; 2020; 11():613286. PubMed ID: 33643295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
